A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348
Age 18 +
Sex Both
Phase Phase 3
Third Opinion Trial Synopsis
This is a study for people with a type of cancer called multiple myeloma who have already had treatment. The study will compare two different medicines to see which one works better and is safer. The study will also look at how these medicines affect the patients' quality of life.
This is a study for people with a type of cancer called multiple myeloma who have already had treatment. The study will compare two different medicines to see which one works better and is safer. The study will also look at how these medicines affect the patients' quality of life.
Third Opinion AI Generated Synopsis
Trial Summary
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
